Skip to main content

Table 2 Changes in the variables from baseline to 52 weeks

From: Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial

 Anagliptin (n = 177)Sitagliptin (n = 176)P valuea
Baseline52 weekP valueBaseline52 weekP value
Low-density lipoprotein cholesterol, mg/dL112 ± 22108 ± 220.01109 ± 22111 ± 220.230.01
Total cholesterol, mg/dL191 ± 29186 ± 270.03186 ± 28190 ± 280.020.001
Triglyceride, mg/dL148 ± 77155 ± 840.42129 ± 68136 ± 820.190.80
Adiponectin, μg/mL4.4 ± 4.44.7 ± 5.20.014.7 ± 4.95.0 ± 5.80.140.23
Aspartate aminotransferase, IU/L28 ± 1827 ± 180.6023 ± 926 ± 190.020.05
Alanine aminotransferase, IU/L29 ± 1928 ± 200.4022 ± 1323 ± 150.410.24
Platelets, 104/μL22 ± 621 ± 60.1422 ± 522 ± 60.920.23
FIB-4 index1.8 ± 0.91.8 ± 0.90.361.7 ± 0.81.9 ± 1.30.030.19
Lipoprotein (a), mg/dLb11.2 ± 9.411.3 ± 9.10.8114.0 ± 11.614.4 ± 12.30.390.65
Malondialdehyde-modified low-density lipoprotein, U/Lb162.9 ± 51.3153.5 ± 50.90.05152.3 ± 42.4153.6 ± 45.60.800.13
Remnant-like particle cholesterol, mmol/Lb7.6 ± 4.98.8 ± 6.80.076.6 ± 4.57.7 ± 5.40.040.91
  1. Data are expressed as mean ± standard deviation
  2. aFor group difference in absolute change from baseline to 52 weeks
  3. bIndicates measured in randomly selected cohort (n =50 on anagliptin, 50 on sitagliptin)